Skip to main content
SpringerLink
Log in
Book cover

Textbook of Gastrointestinal Oncology pp 595–611Cite as

Hereditary Gastrointestinal Cancers

  • Chapter
  • First Online:

  • 870 Accesses

Abstract

While it is true that only a small proportion of patients develop gastrointestinal cancer in the setting of an inherited syndrome, it is important for the medical oncologist to recognize this unique group of patients for several reasons. First, genetic testing of the tumor can have implications for the patient’s prognosis and may help tailor chemotherapy in this age of personalized cancer medicine. Second, affected patients are often at risk for other malignancies either within the gastrointestinal tract or involving other organ systems and, as such, are in need of close clinical surveillance. Lastly, the oncologist is in an excellent position to encourage genetic counseling and testing of at-risk family members. In this chapter we will review familial adenomatous polyposis (FAP) syndrome and hereditary nonpolyposis colon cancer (HNPCC), aka Lynch syndrome, in some detail. We will also discuss polyposis syndromes other than FAP, namely, Peutz-Jegher syndrome and juvenile polyposis as well as hereditary diffuse gastric cancer and inherited pancreatic cancer syndromes.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Hall MJ, Forman AD, Pilarski R, Wiesner G, Giri VN. Gene panel testing for inherited cancer risk. J Natl Compr Cancer Netw. 2014;12(9):1339–46.

    Article  Google Scholar 

  2. Vockley JG, Niederhuber JE. Diagnosis and treatment of cancer using genomics. BMJ. 2015;350:h1832.

    Article  PubMed  Google Scholar 

  3. Stoffel EM, Kastrinos F. Familial colorectal cancer, beyond Lynch syndrome. Clin Gastroenterol Hepatol. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review]. 2014;12(7):1059–68.

    Google Scholar 

  4. Network NCC. Nccn guidelines®. [May 18, 2018]; Available from: https://www.nccn.org/professionals/physician_gls/default.aspx.

  5. ESMO. ESMO clinical practice guidelines. European Society for Medical Oncology; [May 18, 2018]; Available from: http://www.esmo.org/Guidelines.

  6. Grover S, Kastrinos F, Steyerberg EW, Cook EF, Dewanwala A, Burbidge LA, et al. Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA. 2012;308(5):485–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Guarinos C, Juarez M, Egoavil C, Rodriguez-Soler M, Perez-Carbonell L, Salas R, et al. Prevalence and characteristics of MUTYH-associated polyposis in patients with multiple adenomatous and serrated polyps. Clin Cancer Res. 2014;20(5):1158–68.

    Article  CAS  PubMed  Google Scholar 

  8. Borras E, Taggart MW, Lynch PM, Vilar E. Establishing a diagnostic road map for MUTYH-associated polyposis. Clin Cancer Res. 2014;20(5):1061–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Greenson JK, Huang SC, Herron C, Moreno V, Bonner JD, Tomsho LP, et al. Pathologic predictors of microsatellite instability in colorectal cancer. Am J Surg Pathol. 2009;33(1):126–33.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol. 2010;7(3):153–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Bodo S, Colas C, Buhard O, Collura A, Tinat J, Lavoine N, et al. Diagnosis of constitutional mismatch repair-deficiency syndrome based on microsatellite instability and lymphocyte tolerance to methylating agents. Gastroenterology. 2015;149(4):1017–29 e1013.

    Article  PubMed  Google Scholar 

  12. Mork ME, Borras E, Taggart MW, Cuddy A, Bannon SA, You YN, et al. Identification of a novel PMS2 alteration c.505C>G (R169G) in trans with a PMS2 pathogenic mutation in a patient with constitutional mismatch repair deficiency. Familial Cancer. 2016;15(4):587–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Wimmer K, Kratz CP, Vasen HF, Caron O, Colas C, Entz-Werle N, et al. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium ‘care for CMMRD’ (C4CMMRD). J Med Genet. 2014;51(6):355–65.

    Article  CAS  PubMed  Google Scholar 

  14. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352(18):1851–60.

    Article  CAS  PubMed  Google Scholar 

  15. Pinol V, Castells A, Andreu M, Castellvi-Bel S, Alenda C, Llor X, et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA. 2005;293(16):1986–94.

    Article  CAS  PubMed  Google Scholar 

  16. Buchanan DD, Clendenning M, Rosty C, Eriksen SV, Walsh MD, Walters RJ, et al. Tumour testing to identify lynch syndrome in two australian colorectal cancer cohorts. J Gastroenterol Hepatol. 2016.

    Google Scholar 

  17. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23(3):609–18.

    Article  CAS  PubMed  Google Scholar 

  18. Yurgelun MB, Goel A, Hornick JL, Sen A, Turgeon DK, MTt R, et al. Microsatellite instability and DNA mismatch repair protein deficiency in lynch syndrome colorectal polyps. Cancer Prev Res (Phila). 2012;5(4):574–82.

    Article  CAS  Google Scholar 

  19. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261–8.

    Article  CAS  PubMed  Google Scholar 

  20. Dinh TA, Rosner BI, Atwood JC, Boland CR, Syngal S, Vasen HF, et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila). 2011;4(1):9–22.

    Article  Google Scholar 

  21. Kastrinos F, Stoffel EM. History, genetics, and strategies for cancer prevention in Lynch syndrome. Clin Gastroenterol Hepatol. [Historical Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review]. 2014;12(5):715–27; quiz e741–713.

    CAS  Google Scholar 

  22. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 2000;342(2):69–77.

    Article  CAS  PubMed  Google Scholar 

  23. Lynch HT, Kimberling W, Albano WA, Lynch JF, Biscone K, Schuelke GS, et al. Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). I. Clinical description of resource. Cancer. 1985;56(4):934–8.

    Article  CAS  PubMed  Google Scholar 

  24. Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 2011;103(11):863–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the mosaic trial. J Clin Oncol. 2009;27(19):3109–16.

    Article  CAS  PubMed  Google Scholar 

  27. Andre T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the mosaic study. J Clin Oncol. 2015;33(35):4176–87.

    Article  CAS  PubMed  Google Scholar 

  28. Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K, American Society of Clinical O. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2010;28(5):893–901.

    Article  PubMed  Google Scholar 

  29. Ratnayake P, Wakefield CE, Meiser B, Suthers G, Price MA, Duffy J, et al. An exploration of the communication preferences regarding genetic testing in individuals from families with identified breast/ovarian cancer mutations. Familial Cancer. 2011;10(1):97–105.

    Article  PubMed  Google Scholar 

  30. Dove-Edwin I, Sasieni P, Adams J, Thomas HJ. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ. 2005;331(7524):1047.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Choi YH, Briollais L, Win AK, Hopper J, Buchanan D, Jenkins M, et al. Modeling of successive cancer risks in Lynch syndrome families in the presence of competing risks using copulas. Biometrics. 2016.

    Google Scholar 

  32. Moller P, Seppala T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut. 2015.

    Google Scholar 

  33. Haanstra JF, Al-Toma A, Dekker E, Vanhoutvin SA, Nagengast FM, Mathus-Vliegen EM, et al. Prevalence of small-bowel neoplasia in Lynch syndrome assessed by video capsule endoscopy. Gut. 2015;64(10):1578–83.

    Article  PubMed  Google Scholar 

  34. Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, et al. International cancer of the pancreas screening (caps) consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62(3):339–47.

    Article  PubMed  Google Scholar 

  35. Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223–62; quiz 263.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Renkonen-Sinisalo L, Butzow R, Leminen A, Lehtovirta P, Mecklin JP, Jarvinen HJ. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer. 2007;120(4):821–4.

    Article  CAS  PubMed  Google Scholar 

  37. Nebgen DR, Lu KH, Rimes S, Keeler E, Broaddus R, Munsell MF, et al. Combined colonoscopy and endometrial biopsy cancer screening results in women with Lynch syndrome. Gynecol Oncol. 2014;135(1):85–9.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Beggs AD, Latchford AR, Vasen HF, Moslein G, Alonso A, Aretz S, et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut. 2010;59(7):975–86.

    Article  CAS  PubMed  Google Scholar 

  39. Korsse SE, Harinck F, van Lier MG, Biermann K, Offerhaus GJ, Krak N, et al. Pancreatic cancer risk in Peutz-Jeghers syndrome patients: a large cohort study and implications for surveillance. J Med Genet. 2013;50(1):59–64.

    Article  CAS  PubMed  Google Scholar 

  40. Aytac E, Sulu B, Heald B, O’Malley M, LaGuardia L, Remzi FH, et al. Genotype-defined cancer risk in juvenile polyposis syndrome. Br J Surg. 2015;102(1):114–8.

    Article  CAS  PubMed  Google Scholar 

  41. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst. 1994;86(21):1600–8.

    Article  CAS  PubMed  Google Scholar 

  42. Vogelaar IP, van der Post RS, Bisseling TM, van Krieken JH, Ligtenberg MJ, Hoogerbrugge N. Familial gastric cancer: detection of a hereditary cause helps to understand its etiology. Hered Cancer Clin Pract. 2012;10(1):18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Oliveira C, Senz J, Kaurah P, Pinheiro H, Sanges R, Haegert A, et al. Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet. 2009;18(9):1545–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010;47(7):436–44.

    Article  CAS  PubMed  Google Scholar 

  45. de Snoo FA, Bishop DT, Bergman W, van Leeuwen I, van der Drift C, van Nieuwpoort FA, et al. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res. 2008;14(21):7151–7.

    Article  PubMed  Google Scholar 

  46. Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000;119(6):1447–53.

    Article  CAS  PubMed  Google Scholar 

  47. Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond VM, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009;302(16):1790–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Chang MC, Wong JM, Chang YT. Screening and early detection of pancreatic cancer in high risk population. World J Gastroenterol. 2014;20(9):2358–64.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LK Jr, Perrault J, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst. 1997;89(6):442–6.

    Article  CAS  PubMed  Google Scholar 

  50. Canto MI, Hruban RH, Fishman EK, Kamel IR, Schulick R, Zhang Z, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology. 2012;142(4):796–804; quiz e714–795.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Hepatology and Nutrition, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Selvi Thirumurthi & Patrick J. Lynch

  2. Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Eduardo Vilar

  3. Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Eduardo Vilar

Authors
  1. Selvi Thirumurthi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eduardo Vilar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patrick J. Lynch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick J. Lynch .

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Hacettepe University Institute of Cancer, Sihhiye, Ankara, Turkey

    Suayib Yalcin

  2. Department of Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA

    Philip A. Philip

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Thirumurthi, S., Vilar, E., Lynch, P.J. (2019). Hereditary Gastrointestinal Cancers. In: Yalcin, S., Philip, P. (eds) Textbook of Gastrointestinal Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-18890-0_33

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-18890-0_33

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-18888-7

  • Online ISBN: 978-3-030-18890-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation